CN117917240A - Use of compounds for the treatment of herpes simplex virus infection and related diseases or conditions - Google Patents
Use of compounds for the treatment of herpes simplex virus infection and related diseases or conditions Download PDFInfo
- Publication number
- CN117917240A CN117917240A CN202311319192.8A CN202311319192A CN117917240A CN 117917240 A CN117917240 A CN 117917240A CN 202311319192 A CN202311319192 A CN 202311319192A CN 117917240 A CN117917240 A CN 117917240A
- Authority
- CN
- China
- Prior art keywords
- methyl
- simplex virus
- herpes simplex
- crystalline form
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 139
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 208000009889 Herpes Simplex Diseases 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 239000013078 crystal Substances 0.000 claims abstract description 31
- 239000012453 solvate Substances 0.000 claims abstract description 27
- -1 crystalline form Substances 0.000 claims abstract description 26
- 230000000155 isotopic effect Effects 0.000 claims abstract description 18
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims abstract description 16
- 229940002612 prodrug Drugs 0.000 claims abstract description 14
- 239000000651 prodrug Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract description 12
- 239000002207 metabolite Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 67
- 230000005855 radiation Effects 0.000 claims description 53
- 125000001424 substituent group Chemical group 0.000 claims description 44
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 36
- 241000700584 Simplexvirus Species 0.000 claims description 23
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 20
- 239000001530 fumaric acid Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 239000000460 chlorine Chemical group 0.000 claims description 10
- 230000000306 recurrent effect Effects 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 229910052801 chlorine Chemical group 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 claims description 2
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 2
- 208000004898 Herpes Labialis Diseases 0.000 claims description 2
- 206010027201 Meningitis aseptic Diseases 0.000 claims description 2
- 206010067152 Oral herpes Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 2
- 201000004946 genital herpes Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000010484 vulvovaginitis Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- QMPBBNUOBOFBFS-UHFFFAOYSA-N 6-[(6-chloro-2-methylindazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione Chemical compound CN1N=C(C=C(C(/N=C(\NC(N2CC3=NN(C)C=N3)=O)/N(CC(C=C(C(F)=C3)F)=C3F)C2=O)=C2)Cl)C2=C1 QMPBBNUOBOFBFS-UHFFFAOYSA-N 0.000 description 47
- 239000007787 solid Substances 0.000 description 33
- 238000002360 preparation method Methods 0.000 description 30
- 241000700605 Viruses Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000007758 minimum essential medium Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 229910017488 Cu K Inorganic materials 0.000 description 3
- 229910017541 Cu-K Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- NMJJFJNHVMGPGM-UHFFFAOYSA-N butyl formate Chemical compound CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- BFAFXODRFFVZRM-UHFFFAOYSA-N 6-ethylsulfanyl-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione Chemical compound CCSC(N(CC(C=C(C(F)=C1)F)=C1F)C(N1CC2=NN(C)C=N2)=O)=NC1=O BFAFXODRFFVZRM-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- YRZNRFJEBAPCCO-UHFFFAOYSA-N Cn1cc2cc(N)c(Cl)cc2n1 Chemical compound Cn1cc2cc(N)c(Cl)cc2n1 YRZNRFJEBAPCCO-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000007578 melt-quenching technique Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Abstract
The present invention provides the use of a compound of formula (I) or an isomer, salt, N-oxide, metabolite, solvate, salt of a solvate, crystalline form, prodrug, complex, co-crystal, co-amorphous or isotopic form thereof in the manufacture of a medicament for the treatment or prophylaxis of herpes simplex virus infection and associated diseases or conditions in a subject,Wherein R 1、R2、R3、R4、R5、R6、R7, X, m and n are as defined herein. The compounds described herein have the effect of inhibiting herpes simplex virus type 1 and herpes simplex virus type 2.
Description
Technical Field
The present invention relates to the use of a salt, crystalline form, prodrug or isotopic form comprising a specific compound or an isomer, salt, N-oxide, solvate, salt of a solvate thereof, for the manufacture of a medicament for the treatment or prophylaxis of a herpes simplex virus infection and associated diseases or conditions in a subject.
Background
In the acute infectious diseases, most of the infectious diseases are viral infectious diseases, and the incidence rate and the death rate of the viral infectious diseases are high. Individuals such as viruses are extremely tiny, lack independent metabolic capability, and exist parasitically as pathogenic microorganisms. Viruses are of a wide variety, and at present, many viruses with high infectivity and pathogenicity to human beings have been found, and the viruses often cause local and even global infectious diseases to outbreak, and have great harm to human society, such as herpes simplex virus. Some viruses can also infect animals, causing various light to severe diseases, and at the same time, animals become sources of infection for these viruses, making humans overwhelm them.
Herpes simplex virus (herpes simplex virus, HSV) is a typical representation of herpes viruses and is known as dermatitis blisters, i.e. herpes simplex, occurring in the acute phase of infection. Herpes simplex virus can cause a variety of diseases in humans, such as gingivitis (gingivostomatitis), keratoconjunctivitis (keratoconjunctivitis), encephalitis (ENCEPHALITIS), infection of the reproductive system and neonatal infections.
In view of the foregoing, there is a great need in the art to develop inhibitors for inhibiting replication of herpes simplex virus for use in the treatment of herpes simplex virus infections and diseases or conditions associated therewith.
Disclosure of Invention
The present invention provides a solution to the above problems existing in the prior art.
In a first aspect of the invention there is provided the use of a compound of formula (I), or an isomer, salt, N-oxide, metabolite, solvate, salt of a solvate, crystalline form, prodrug, complex, co-crystal, co-amorphous or isotopic form thereof, in the manufacture of a medicament for the treatment or prophylaxis of a herpes simplex virus infection and associated diseases or conditions in a subject,
Wherein the method comprises the steps of
Each R 1、R2、R3、R4、R5、R6、R7 is independently H or substituted or unsubstituted C 1-C6 alkyl;
X is halogen;
m is 0,1,2 or 3;
n is 0, 1,2, 3,4 or 5.
In another aspect of the invention there is provided the use of a compound of formula (I) or an isomer, salt, N-oxide, metabolite, solvate, salt of a solvate, crystalline form, prodrug, complex, co-crystal, co-amorphous or isotopic form thereof in the manufacture of a medicament for inhibiting herpes simplex virus.
The inventive research shows that the compound has the effect of inhibiting the herpes simplex virus and has good potential effect in the aspect of treating or preventing the herpes simplex virus infection and related diseases or symptoms thereof.
Drawings
FIG. 1 is a statistical graph of the activity of compounds in biological examples to inhibit herpes simplex virus.
FIG. 2 is an X-ray powder diffraction pattern of crystalline form A of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 3 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form A of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 4 is an X-ray powder diffraction pattern of crystalline form B of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 5 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form B of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 6 is an X-ray powder diffraction pattern of crystalline form C of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 7 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form C of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 8 is an X-ray powder diffraction pattern of crystalline form D of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 9 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form D of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 10 is an X-ray powder diffraction pattern of crystalline form E of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 11 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form E of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 12 is an X-ray powder diffraction pattern of crystalline form F of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 13 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form F of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 14 is an X-ray powder diffraction pattern of crystalline form G of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 15 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form G of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 16 is an X-ray powder diffraction pattern of crystalline form H of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 17 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form H of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 18 is an X-ray powder diffraction pattern of crystalline form I of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 19 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form I of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 20 is an X-ray powder diffraction pattern of crystalline form J of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 21 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form J of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 22 is an X-ray powder diffraction pattern of crystalline form K of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione. Wherein the abscissa is 2θ (°), and the ordinate is intensity (count).
FIG. 23 is a Thermogravimetric (TGA) and Differential Scanning Calorimetric (DSC) profile of crystalline form K of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione.
FIG. 24 is an X-ray powder diffraction pattern of crystalline form A of compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and fumaric acid.
Detailed Description
The term "herpes simplex virus" belongs to the subfamily alphavirus of the herpesviridae, has typical morphological structural characteristics of the herpesvirus, has a core of double-stranded linear DNA, is composed of a long fragment and a short fragment, has a length of about 150kb, can code more than 100 polypeptides, and has a part of polypeptides closely related to virus infection and cell destruction. The number of viral envelope glycoproteins is 11, gB, gC, gD, gE, gG, gH, gI, gL, gK and gM respectively, which play an important role in volatilizing the virus during the pathogenic process and are also the main antigens for inducing the immune response of the organism. The viruses can be classified into herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) according to antigenicity differences, the herpes simplex virus type 1 is mainly obtained from foci of lips, and the herpes simplex virus type 2 can be separated from foci of genitals. In particular, the herpes simplex virus comprises (e.g., is selected from) herpes simplex virus type 1 and/or herpes simplex virus type 2; preferably, herpes simplex virus type 1 (HSV-1) is herpes simplex virus type 1 GDV011; and/or, herpes simplex virus type 2 (HSV-2) is herpes simplex virus type 2 GDV017.
Herpes simplex virus type 1 causes local damage to the orofacial area, particularly on the mucous membranes (mouth and throat), at the skin mucosal edges (lips), and on the cornea (eyes). HSV-2 infection is mostly found in the genital tract.
Herpes simplex virus infection and its related diseases or conditions include diseases or conditions caused by herpes simplex virus, e.g., it includes (e.g., is selected from the group consisting of): clinical herpes (primary and recurrent), herpetic eczema (primary), traumatic herpes (primary or recurrent), gingivitis (primary), vulvovaginitis (primary, recurrent), genital herpes (primary, recurrent), keratoconjunctivitis (primary and recurrent), meningoeencephalitis (primary), neonatal herpes simplex virus infection, aseptic meningitis, and/or herpes labialis, etc.
In the present invention, inhibition of herpes simplex virus may be performed in a subject or in vitro. Inhibition of herpes simplex virus in a subject may be accomplished to treat or prevent herpes simplex virus infection and related diseases or conditions. Forms of inhibiting herpes simplex virus in vitro, including positive control drugs, research drugs and the like used for resisting the herpes simplex virus, are used in activities such as in vitro biological activity research and the like.
The invention also includes the combination of the compound of formula (I) with other antiviral agents (e.g. interferon, acyclovir, valacyclovir, etc.) or agents for the treatment of bacterial infections (e.g. antibiotics) for the treatment or prophylaxis of herpes simplex virus infections and diseases or conditions associated therewith, for the manufacture of a pharmaceutical combination or pharmaceutical composition for use in combination.
The compounds of the present application may exist in an isomer, such as a stereoisomer (enantiomer, diastereomer, cis-trans isomer), depending on the structure thereof. The present application thus relates to enantiomers or diastereomers and their respective mixtures. The stereoisomerically pure constituents can be separated in a known manner from such mixtures of enantiomers and/or diastereomers.
When the compounds of the present application may exist as optical isomers, the compounds of the present application are generally substantially pure optical isomers.
If the compounds of the present application are in tautomeric forms, the present application encompasses all tautomeric forms.
The compounds of the application may be present in free form, for example as a free base or as a free acid or as a zwitterion, or may be present in the form of a salt. The salt may be any salt commonly used in pharmacy, organic or inorganic addition salts, in particular any physiologically acceptable organic or inorganic addition salt.
For the purposes of the present application, preferred salts are the physiologically acceptable salts of the compounds according to the application. However, salts which are not suitable for pharmaceutical use per se but which can be used, for example, for the isolation or purification of the compounds according to the application are also included.
The term "physiologically acceptable salts" refers to the relatively non-toxic, inorganic or organic acid addition salts of the compounds described herein, see for example S.M. Berge et al, "Pharmaceutical Salts", J.Pharm. Sci.1977,66,1-19.
Physiologically acceptable salts of the compounds according to the application encompass acid addition salts of inorganic acids, carboxylic acids and sulphonic acids, for example salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid, disulphonic acid, sulphamic acid, phosphoric acid, nitric acid, or salts with organic acids, the organic acid is, for example, formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, caproic acid, heptanoic acid, undecanoic acid, dodecanoic acid, benzoic acid, salicylic acid, 2- (4-hydroxybenzoyl) -benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, octanoic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectate acid, persulfuric acid, 3-phenylpropionic acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, pantothenic acid, mucic acid, succinic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, gluconic acid, mandelic acid, ascorbic acid, glucoheptonic acid, glycerophosphate, aspartic acid, sulfosalicylic acid or thiocyanic acid. Particularly preferred are p-toluene sulfonic acid and/or fumarate salts.
The application includes all possible salts of the compounds of the application, which are single salts or any mixture of the salts in any ratio, for example 3:1, 2:1, 1:1, 1:2.
Solvates are, for the purposes of the present application, terms for those forms of the compounds of the present application which form complexes with solvent molecules by coordination in solid or liquid form. Hydrates are a specific form of solvate in which coordination with water occurs. In the context of the present application, hydrates are preferred as solvates.
The application also includes all suitable isotopic forms of the compounds of the present application. Isotopic forms of the compounds of the present application are defined as: a compound in which at least one atom is replaced with an atom having the same atomic number but an atomic mass different from the atomic mass usually or mainly existing in nature. Examples of isotopes that can be incorporated into compounds of the application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3 H (tritium )、13C、14C、15N、17O、18O、32P、33P、33S、34S、35S、36S、18F、36Cl、82Br、123I、124I、129I and 131 i. Certain isotopic variants of compounds of the application, such as those incorporating one or more radioisotopes such as 3 H or 14 C, are particularly preferred for use in the study of drug and/or matrix tissue distribution.
In addition, prodrugs of the compounds of the present application are also encompassed by the present application. The term "prodrug" encompasses compounds which may be biologically active or inactive themselves, but which are converted (e.g. by metabolism or hydrolysis) during their residence time in the body to the compounds described herein. Prodrugs of the compounds of the present application may be produced, for example, by replacing suitable functional groups present in the compounds of the present application with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in Design of Prodrugs of H.Bundgaard (Elsevier, 1985)).
The compounds of the present application may be in solid form, such as amorphous, crystalline (either single crystalline or polymorphic) or mesogenic (mesomorph).
As used herein, the term "amorphous form" refers to an amorphous solid state form of a substance.
As used herein, the term "crystalline form" refers to a crystalline solid state form of a substance, i.e., a crystalline form of the same molecule, and as a result of the arrangement or conformation of the molecules in the crystal lattice. In particular, the crystalline form may be a single crystalline form or a polymorphic form.
Furthermore, the present application includes all possible polymorphs (single polymorphs or mixtures of more than one polymorphs in any ratio) of the compounds of the present application.
As used herein, the term "polymorph" refers to a crystal structure in which molecules can crystallize in different crystal package arrangements and all have the same elemental composition. For example, the same material has two or more spatial arrangements and unit cell parameters, forming multiple crystalline forms.
As used herein, the term "mesogenic form" refers to a substance (e.g., liquid crystal) that exists in a state between liquid and solid states. In the mesogenic form, the same molecules of the substance may be oriented in an organized manner (e.g., crystalline), and the substance may flow like a liquid.
Thus, the present application includes all possible salts, crystalline forms, metabolites, hydrates, solvates, prodrugs (e.g. esters) and diastereoisomeric forms of the compounds of the application, either as a single salt, crystalline form, metabolite, hydrate, solvate, prodrug (e.g. ester) or diastereoisomeric form, or as a mixture of more than one salt, crystalline form, metabolite, hydrate, solvate, prodrug (e.g. ester) or diastereoisomeric form in any ratio.
The compounds of the application intended for pharmaceutical use may be administered as crystalline or amorphous products, or mixtures thereof. Compositions, for example as solid suppositories, powders or films, can be obtained by processes such as precipitation, crystallization, freeze-drying, spray-drying or evaporative drying. Microwave or radiation drying may be used for this purpose.
The compounds of the application may be admixed with physiologically acceptable/pharmaceutically acceptable excipients to form pharmaceutical compositions, the choice of which is dependent upon the intended method of administration of the pharmaceutical composition (e.g., oral, inhalation, topical, nasal, rectal, transdermal or injectable administration).
As used herein, the term "physiologically acceptable/pharmaceutically acceptable excipient" refers to an excipient that does not cause significant irritation to an organism and does not interfere with the biological activity and properties of the active ingredient (e.g., a compound of the application) being administered.
For the purposes of the present invention, unless otherwise indicated, substituents have the following meanings:
The term "substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are independently substituted with a corresponding number of substituents. Substituents are only in their possible chemical positions and the person skilled in the art is able to determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, the substituents may be one or more groups independently selected from C 1-C6 alkyl, C 1-C6 alkoxy, C 1-C6 alkylthio, C 1-C6 alkylamino, halogen, mercapto, hydroxy, nitro, cyano, C 3-C6 cycloalkyl, C 2-C6 heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carboxylate groups.
The term "halogen", "halogen atom" or "halo" means fluorine, chlorine, bromine and iodine, in particular bromine, chlorine or fluorine, preferably chlorine or fluorine.
The term "C 1-C6 alkyl" denotes a straight-chain or branched alkyl group having the specifically specified number of carbon atoms (e.g., one, two, three, four, five or six carbon atoms), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl or 1, 2-dimethylbutyl. If the number of carbon atoms is not specified, the term "alkyl" generally denotes a straight-chain or branched alkyl group having from 1 to 9, in particular from 1 to 6, preferably from 1 to 4, carbon atoms. In particular, the alkyl group has 1,2, 3, 4, 5 or 6 carbon atoms ("C 1-C6 -alkyl"), for example methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, pentyl, isopentyl, hexyl, 2-methylbutyl, 1-ethylpropyl, 1, 2-dimethylpropyl, neopentyl, 1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 2, 3-dimethylbutyl, 1, 3-dimethylbutyl or 1, 2-dimethylbutyl. Preferably, the alkyl group has 1,2 or 3 carbon atoms ("C 1-C3 -alkyl"), such as methyl, ethyl, n-propyl or isopropyl.
As used herein, the term "subject" refers to an animal, including but not limited to, a primate (e.g., human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. In particular, the subject is 0 years old or older, 1 year old or older, 2 years old or older, 4 years old or older, 5 years old or older, 10 years old or older, 12 years old or older, 13 years old or older, 15 years old or older, 16 years old or older, 18 years old or older, 20 years old or older, 25 years old or older, 30 years old or older, 35 years old or older, 40 years old or older, 45 years old or older, 50 years old or older, 55 years old or older, 60 years old or older, 65 years old or older, 70 years old or older, 75 years old or older, 80 years old or older, 85 years old or older, 90 years old or older, 95 years old or older, 100 years old or older, or 105 years old or older.
In a specific embodiment, the subject is a human, such as a child (e.g., a human aged 0-18 years or a human aged 0-14 years), an adult (e.g., a human aged 19-59 years), or an elderly human (e.g., a human aged 60 years or older).
In a particular embodiment, in the compound of formula (I), R 1 and R 2 are each independently unsubstituted C 1-C6 alkyl, preferably each independently methyl.
In a particular embodiment, in the compounds of formula (I), R 3、R4、R5、R6、R7 are each independently H.
In a particular embodiment, in the compound of formula (I), each X may be the same or different. For example, in the compound of formula (I), the substituents X on the indazole ring may be the same or different from each other, the substituents X on the benzene ring in the benzyl group may be the same or different from each other, and the substituents X on the indazole ring and the substituents X on the benzene ring in the benzyl group may be the same or different.
In a particular embodiment, in the compound of formula (I), the substituent X on the indazole ring may be the same or different from the substituent X on the benzene ring in the benzyl group. Specifically, in the compound of formula (I), the substituents X on the indazole ring are each independently fluorine or chlorine, preferably chlorine; and/or the substituents X on the benzene ring in the benzyl group are each independently fluorine or chlorine, preferably fluorine.
In a specific embodiment, in the compound of formula (I), m is 1 or 2, for example 1. Specifically, when m is 2, the substituent X on the indazole ring is a 4, 6-position substituent, a 4, 7-position substituent, or a 6, 7-position substituent. Specifically, when m is 2, the substituents X on the indazole ring are the same or different independently of each other. More specifically, when m is 2, X is a 4, 6-dichloro substituent, 4, 7-dichloro substituent, 6, 7-dichloro substituent, 4, 6-difluoro substituent, 4, 7-difluoro substituent, 6, 7-difluoro substituent, 4-chloro-6-fluoro substituent, 4-fluoro-6-chloro substituent, 4-chloro-7-fluoro substituent, 4-fluoro-7-chloro substituent, 6-chloro-7-fluoro substituent, or 6-fluoro-7-chloro substituent. Specifically, when m is 1, X is a 4-position substituent, a 6-position substituent, or a 7-position substituent. More specifically, when m is 1, X is a 4-fluoro substituent, a 4-chloro substituent, a 6-fluoro substituent, a 6-chloro substituent, a 7-fluoro substituent, or a 7-chloro substituent.
In a specific embodiment, in the compound of formula (I), n is 2, 3 or 4, for example 3.
In a specific embodiment, in the compound of formula (I), when n is 3, X is a2, 3, 4-position substituent, a2, 3, 6-position substituent, a2, 4, 5-position substituent, a2, 5, 6-position substituent, a3, 4, 5-position substituent, a3, 5, 6-position substituent, or a4, 5, 6-position substituent. Specifically, when n is 3, the substituents X on the benzene ring in the benzyl group are the same or different, preferably the same, independently of each other. More specifically, when n is 3, X is a2, 3, 4-trifluoro substituent, a2, 3, 6-trifluoro substituent, a2, 4, 5-trifluoro substituent, a2, 5, 6-trifluoro substituent, a3, 4, 5-trifluoro substituent, a3, 5, 6-trifluoro substituent, or a4, 5, 6-trifluoro substituent, preferably a2, 4, 5-trifluoro substituent.
In a specific embodiment, the compound of formula (I) has the following structure:
Wherein R 1、R2, X and n are as defined above in the present application.
In a specific embodiment, the compound of formula (I) is
Or a salt, isomer, N-oxide, metabolite, solvate, salt of a solvate, crystalline form, prodrug, complex, co-crystal, co-amorphous or isotopic form thereof.
Specifically, the compound of formula (I) isAn amorphous form, a crystalline form (which may be a single crystalline form or a polymorphic form) or an isotopic form (e.g., a deuterated isotopic form); or an amorphous form, a crystalline form (which may be a single crystalline form or a polymorphic form) or an isotopic form (such as a deuterated isotopic form) of a salt thereof (e.g., fumarate); or an amorphous form, a crystalline form (which may be a single crystalline form or a polymorphic form) or an isotopic form (e.g., a deuterated isotopic form) of complexes thereof with other compounds (e.g., fumaric acid); or in the form of a co-crystal or isotope with other compounds such as fumaric acid.
In particular, specific compounds encompassed by the compound of formula (I) (e.g., the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione) and methods for their preparation are known in the art.
For example, the specific compound may be in a crystalline form selected from one of form a, form B, form C, form D, form E, form F, form H, form I, form G, form J, form K, or a mixture of two or more thereof;
Wherein,
Form a is characterized by using Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any three or more of 4.30, 12.30, 12.87, 24.61;
form B is characterized by the use of Cu-ka radiation, the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° including 22.20, 23.26, 26.86;
Form C is characterized by using Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any three or more of 11.26, 12.55, 18.85, 19.49;
The crystal form D is characterized in that Cu-K alpha radiation is used, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2 theta value +/-0.2 degrees comprise more than any three of 9.89, 12.83, 13.67 and 15.41;
Form E is characterized by the use of Cu-ka radiation, the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° including 6.60, 9.63, 13.25;
Form F is characterized by using Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any three or more of 7.44, 8.16, 14.65, 21.51;
form H is characterized by using Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any three or more of 9.16, 11.69, 19.52, 24.00;
form I is characterized by the use of Cu-ka radiation, the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° including 12.98, 13.24, 26.11;
Form G is characterized by the use of Cu-ka radiation, the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° including 8.76, 10.89, 17.73;
form J is characterized by the use of Cu-ka radiation, the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° including 17.00, 26.42, 27.99;
Form K is characterized by the use of Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any three or more of 8.29, 8.83, 14.27, 23.56.
Specifically, the crystalline forms of the compounds of the present application were characterized using an X-ray powder diffractometer PANALYTICAL EMPYREAN (PANALYTICAL, NL) with a2 theta scan angle from 3 deg. to 45 deg., a scan step size of 0.013 deg., a test time of 5 minutes 8 seconds, a light pipe voltage and current of 45kV and 40mA, respectively, and a sample pan of zero background sample pan.
In particular, the crystalline form of the compounds of the present application is a single crystalline form (e.g., form a or form E); or the crystalline form of the compound of the application is a mixture (e.g., polymorphic form) comprising at least form a and/or form E. For example, the crystalline form of the compounds of the present application is a mixture (e.g., polymorph) consisting of form a and one or more other crystalline forms different from forms a and E, a mixture (e.g., polymorph) consisting of form a, form E, and optionally one or more other crystalline forms different from forms a and E, or a mixture (e.g., polymorph) consisting of form E and one or more other crystalline forms different from forms a and E.
As used herein, the term "other crystalline forms other than forms a and E" refers to crystalline forms of the compounds of the present application that are different from forms a and E, preferably pharmaceutically acceptable crystalline forms of the compounds of the present application that are different from forms a and E.
In particular, the crystalline form of the compounds of the present application may be a solvate. In particular, crystalline form a or I of the compounds of the present application may be a solvate.
The term "solvates" refers to those forms of the crystalline forms of the compounds of the present application that are used to form complexes with molecules of solvents (e.g., water, organic solvents such as DMF, formic acid, toluene, etc.) by coordination. Hydrates are a specific form of solvate in which coordination with water occurs. For example, the solvate may be a hydrate.
In particular, the crystalline form of the compounds of the present application may be anhydrate. Specifically, crystalline form C, E or K of the compounds of the present application may be anhydrate.
Specifically, the characteristic diffraction peak of the X-ray powder diffraction pattern expressed as 2 theta value + -0.2 DEG using Cu-K alpha radiation also includes any one or more of 10.65, 13.79, 20.67.
Specifically, form a uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 4.30, 10.65, 12.30, 12.87, 13.79, 20.67, 24.61.
More specifically, form a uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 13.19, 14.94, 18.91, 24.95.
Specifically, the differential scanning calorimetric profile of form A has endothermic peaks at 167.3 ℃ + -2 ℃, 202.5 ℃ + -2 ℃, 211.2 ℃ + -2 ℃ and 239.0 ℃ + -2 ℃.
Specifically, the thermogravimetric profile of form a loses less than 6% (specifically 5.2%) of weight when heated to 150 ℃ ± 2 ℃ and undergoes decomposition at 275 ℃ ± 2 ℃.
In a specific embodiment, form B uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further comprise any one or more of 11.65, 15.92, 20.38.
In a specific embodiment, form B uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 11.65, 15.92, 20.38, 22.20, 23.26, 26.86.
Specifically, form B uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 8.57, 12.40, 16.18, 17.18.
Specifically, the differential scanning calorimetry pattern of form B has endothermic peaks at 155.2 ℃ ± 2 ℃, 219.9 ℃ ± 2 ℃ and 239.0 ℃ ± 2 ℃ and exothermic peaks at 221.9 ℃ ± 2 ℃.
Specifically, the thermogravimetric profile of form B loses less than 9% (specifically 8.6%) of weight when heated to 200 ℃ ± 2 ℃ and undergoes decomposition at 275 ℃ ± 2 ℃.
Specifically, form C uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 12.80, 16.27, 26.91.
Specifically, form C uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 11.26, 12.55, 12.80, 16.27, 18.85, 19.49, 26.91.
More specifically, form C uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 10.47, 10.93, 18.17, 18.49.
Specifically, the differential scanning calorimetry pattern of form C has endothermic peaks at 218.6 ℃ ± 2 ℃ and 239.0 ℃ ± 2 ℃ and exothermic peaks at 221.7 ℃ ± 2 ℃.
Specifically, the thermogravimetric profile of form C loses less than 0.5% (specifically 0.4%) when heated to 150 ℃ ± 2 ℃ and undergoes decomposition at 275 ℃ ± 2 ℃.
Specifically, form D uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 13.98, 19.85, 25.02.
Specifically, form D uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 9.89, 12.83, 13.67, 13.98, 15.41, 19.85, 25.02.
More specifically, form D uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 7.53, 22.05, 22.73, 25.94.
Specifically, the differential scanning calorimetric profile of form D has endothermic peaks at 146.2.+ -. 2 ℃, 150.7.+ -. 2 ℃, 160.4.+ -. 2 ℃, 220.0.+ -. 2 ℃ and 240.1.+ -. 2 ℃ and exothermic peaks at 222.3.+ -. 2 ℃.
Specifically, the thermogravimetric profile of form D loses less than 12% (specifically 11.5%) of weight when heated to 200 ℃ ± 2 ℃ and disintegrates at 275 ℃ ± 2 ℃.
In particular, form E uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 16.21, 17.56, 19.87.
In particular, form E uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 6.60, 9.63, 13.25, 16.21, 17.56, 19.87.
More specifically, form E uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 23.34, 24.55, 26.08.
Specifically, the differential scanning calorimetry pattern of form E has an endothermic peak at 238.7 ℃ ± 2 ℃.
Specifically, the thermogravimetric profile of form E did not lose weight (specifically 0%) when heated to 200 ℃ ± 2 ℃ and decomposed at 275 ℃ ± 2 ℃.
Specifically, form F uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 19.70, 24.61, 26.62.
Specifically, form F uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 7.44, 8.16, 14.65, 19.70, 21.51, 24.61, 26.62.
More specifically, form F uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 16.33, 19.35, 22.72, 29.58.
Specifically, the differential scanning calorimetry pattern of form F has endothermic peaks at 208.1 ℃ ± 2 ℃ and 239.1 ℃ ± 2 ℃ and exothermic peaks at 210.3 ℃ ± 2 ℃.
Specifically, the thermogravimetric profile of form F loses less than 10% (specifically 9.6%) when heated to 150 ℃ ± 2 ℃ and disintegrates at 275 ℃ ± 2 ℃.
Specifically, form G uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 15.18, 26.53, 27.42.
Specifically, form G used Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° included 8.76, 10.89, 15.18, 17.73, 26.53, 27.42.
Specifically, form G uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 7.57, 12.59, 18.85, 21.30.
Specifically, the differential scanning calorimetric pattern of form G has endothermic peaks at 140.2.+ -. 2 ℃, 219.9.+ -. 2 ℃ and 238.9.+ -. 2 ℃ and exothermic peaks at 142.4.+ -. 2 ℃ and 225.7.+ -. 2 ℃.
Specifically, the thermogravimetric profile of form G loses less than 17% (specifically 16.4%) of weight when heated to 200 ℃ ± 2 ℃ and undergoes decomposition at 275 ℃ ± 2 ℃.
Specifically, form H uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 15.12, 18.61, 22.01.
Specifically, form H uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 9.16, 11.69, 15.12, 18.61, 19.52, 22.01, 24.00.
More specifically, form H uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 14.33, 17.88, 25.78.
Specifically, the differential scanning calorimetric profile of form H has an endothermic peak at 145 ℃ + -2 ℃, 227.5 ℃ + -2 ℃, 239.4 + -2 ℃ and an exothermic peak at 239 ℃ + -2 ℃.
Specifically, the thermogravimetric profile of form H loses less than 15% (specifically 14.4%) of weight when heated to 200 ℃ ± 2 ℃ and undergoes decomposition at 275 ℃ ± 2 ℃.
Specifically, the characteristic diffraction peak of the X-ray powder diffraction pattern expressed as 2 theta value + -0.2 DEG using Cu-K alpha radiation also includes any one or more of 4.35, 19.99, 29.26.
Specifically, form I uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 4.35, 12.98, 13.24, 19.99, 26.11, 29.26.
More specifically, form I uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 7.03, 10.94, 25.61.
Specifically, the differential scanning calorimetry pattern of the crystal form I has endothermic peaks at 165.4+/-2 ℃, 209.3+/-2 ℃ and 239.5+/-2 ℃ and exothermic peaks at 213.8 +/-2 ℃.
Specifically, the thermogravimetric analysis of form I loses less than 3% (specifically 2.1%) of weight when heated to 150 ℃ ± 2 ℃ and undergoes decomposition at 275 ℃ ± 2 ℃.
Specifically, form J uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 16.58, 28.07, 28.14, 29.88.
Specifically, form J uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include 16.58, 17.00, 26.42, 27.99, 28.07, 28.14, 29.88.
More specifically, form J uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 26.11, 29.94, 34.78.
Specifically, the differential scanning calorimetry pattern of form J has endothermic peaks at 132.9 ℃ + -2 ℃, 227.8 ℃ + -2 ℃ and 239.1 ℃ + -2 ℃ and exothermic peaks at 197.7 ℃ + -2 ℃ and 231.0 ℃ + -2 ℃.
Specifically, the thermogravimetric profile of form J loses less than 11% (specifically 10.4%) when heated to 200 ℃ ± 2 ℃ and disintegrates at 275 ℃ ± 2 ℃.
Specifically, form K uses Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values±0.2° further include any one or more of 10.47, 12.60, 17.13.
Specifically, form K uses Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values±0.2° include 8.29, 8.83, 10.47, 12.60, 14.27, 17.13, 23.56.
More specifically, form K uses Cu-ka radiation and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° further include any one or more of 12.27, 15.67, 17.43, 19.90.
Specifically, the differential scanning calorimetry pattern of form K has an endothermic peak at 228.2 ℃ ±2 ℃.
Specifically, the thermogravimetric profile of form K loses less than 1.5% (specifically 1.2%) when heated to 200 ℃ ± 2 ℃ and decomposes at 275 ℃ ± 2 ℃.
In particular, the specific compounds encompassed by the compounds of formula (I) (e.g., the compounds (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione) may be in crystalline form, which crystalline forms and processes for their preparation are described in WO2022/138987A1 and/or WO2022/138988A1, the above-mentioned patent applications being incorporated herein by reference.
For example, the isotopic form of the particular compound described above may be represented by any one of the following structural formulas:
/>
Specifically, deuterated isotopic forms of the specific compounds described above, methods of preparation, and the like are described in CN114507221a, which is incorporated herein by reference.
For example, the salt of the above specific compound (e.g., compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione) is maleate, fumarate or tosylate, and reference may be made to the descriptions of WO2022/138987A1 and/or WO2022/138988A1, the above-mentioned patent application being incorporated herein by reference. The crystalline forms of the salts of the above specific compounds are selected from the crystalline forms of the fumarate or tosylate salts of the compounds, the specific structures and methods of preparation of which are described in WO2022/138987A1 and/or WO2022/138988A1, the above-mentioned patent applications being incorporated herein by reference.
Specifically, the crystalline form of the salt of the compound of the application is a single crystalline form; or the crystalline form of a salt of a compound of the application is a mixture comprising at least two crystalline forms (e.g., polymorphs). Preferably, the crystalline form of the salt of the compound of the application is a single crystalline form or a polymorph of the fumarate salt of the compound, for example as a mixture of two crystalline forms of the fumarate salt of the compound.
In particular, the crystalline form of a salt of a compound of the application may be a solvate.
In particular, the crystalline form of a salt of a compound of the application may be anhydrate.
The application also includes complexes or co-crystals or co-amorphous forms of each particular compound encompassed by the application with other molecules, which may be other active compounds, co-crystal formations, and the like.
The term "co-crystal" refers to crystals of an Active Pharmaceutical Ingredient (API) and a co-crystal former (cocrystals former, CCF) bonded by hydrogen bonding, van der waals forces, pi-pi conjugation, or halogen bonding, wherein the pure states of the API and CCF are both solid at room temperature and there is a fixed stoichiometric ratio between the components. A co-crystal is a multi-component crystal that includes both binary co-crystals formed between two neutral solids and multi-component co-crystals formed between a neutral solid and a salt or solvate.
The term "co-amorphous" refers to a single-phase amorphous binary or multi-component system having a single glass transition temperature (Tg) formed by non-covalent bonds, ionic bonds, or no interaction forces of an Active Pharmaceutical Ingredient (API) with other physiologically acceptable small molecule substances (e.g., API 2 or small molecule pharmaceutical excipients, etc.), wherein the active pharmaceutical ingredient and the other physiologically acceptable small molecule substances are solid at room temperature. These components are intimately mixed together at the molecular level in the co-amorphous, nor are there fixed stoichiometric ratios between the components. The "co-amorphous" samples can be prepared by melt and solvent-based processes such as spray drying, solvent evaporation, freeze drying, supercritical fluid precipitation, melt quenching, hot melt extrusion, ball milling, cryogenic milling, and the like. X-ray powder diffraction (XRPD) together with Differential Scanning Calorimetry (DSC) can be used to identify whether a sample is "co-amorphous" after preparation, for example by measuring the absence of bragg peaks and the occurrence of a single glass transition temperature.
In one embodiment, the crystalline forms of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and fumaric acid are used.
Specifically, the crystalline form is crystalline form a, which uses cu—kα radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values±0.2° include any three selected from 10.94, 19.06, 23.50, 24.66.
Preferably, crystalline form a, which uses Cu-ka radiation, further comprises any one or more of 9.5, 13.81, 18.61, 22.59, 23.8, or further comprises any one or more of 7.81, 10.14, 11.50, 11.93, 12.31, or further comprises any one or more of 14.73, 20.87, 21.49, 21.97, 25.39, of the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 °.
More preferably, crystalline form a uses Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any one or more of 10.94, 19.06, 23.50, 24.66, 9.5, 13.81, 18.61, 22.59, 23.8, or further include any one or more of 7.81, 10.14, 11.50, 11.93, 12.31, and/or further include any one or more of 14.73, 20.87, 21.49, 21.97, 25.39.
Most preferably, crystalline form a uses Cu-ka radiation and the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° is shown in fig. 24.
Specifically, the molar ratio of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione to fumaric acid in the crystalline form (e.g., crystalline form A) is 1:1.
In a specific embodiment, the application provides the use of the crystalline forms (e.g., crystalline form a) of the compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and fumaric acid of the application in the manufacture of a medicament for the treatment or prophylaxis of herpes simplex virus infection and its associated diseases or disorders in a subject; preferably, the use is in the manufacture of a medicament for inhibiting herpes simplex virus.
The crystalline forms of the above compound (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and fumaric acid may be referred to in CN114591304A, the above patent application being incorporated herein by reference.
The various embodiments described herein, or of different preferred classes of embodiments, may be combined arbitrarily unless otherwise indicated.
The present invention is illustrated below by way of examples, but it should not be construed that the scope of the inventive subject matter is limited to the following examples. All techniques implemented based on the above description of the invention are within the scope of the invention. The compounds or reagents used in the following examples are commercially available or may be prepared by conventional methods known to those skilled in the art; the laboratory apparatus used is commercially available.
Examples
I. preparation example
1. (6E) Preparation of (E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-e-2, 4-dione
To a solution of 6-ethylsulfanyl-3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazine-2, 4 (1H, 3H) -dione (450 mg,1.091 mmol) and 6-chloro-2-methyl-2H-indazol-5-amine (258 mg, 1.319 mmol) in THF (10 mL) was first added drop-wise LHMDS (1M in THF, 1.00mL,1.00 mmol) at 0deg.C, stirred for 30min, then LHMDS (1M in THF, 1.00mL,1.00 mmol) was added drop-wise with continuous stirring. The reaction mixture was stirred at 0 ℃ for 2.5h, followed by 40min at room temperature. The reaction was quenched with aqueous NH 4 Cl and the aqueous layer was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO 4 and concentrated under reduced pressure. The residue was recrystallized from methylene chloride/isopropyl ether (5:1 by volume) and subsequently dried in vacuo to give a pale pink solid. The pale pink solid was dispersed in 5mL of isopropanol, stirred, heated to reflux, cooled and suction filtered. The resulting cake was dried in vacuo to give (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione (380.1 mg) as a solid.
2. (6E) Preparation of each of the crystalline forms of (E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-e-2, 4-dione
2.1 Preparation method of Crystal form A
20.6Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 10.0mL of ethylene glycol dimethyl ether to be completely dissolved, and then left open at room temperature for 2 weeks, followed by centrifugal separation (10000 rpm,4 min) to give crystalline form A of the compound of the present application.
2.2 Preparation method of Crystal form B
15.0Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, 0.8mL of dioxane was added to completely dissolve, 4.0mL of n-heptane was then added to the solution rapidly, stirring was carried out at room temperature for 1 hour, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give form B of the compound of the present application.
2.3 Preparation method of Crystal form C
15.0Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 0.8mL of dioxane to completely dissolve, 4.0mL of isopropyl ether was then added to the solution, stirred at room temperature for 1 hour, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give form C of the compound of the present application.
2.4 Preparation method of crystal form D
19.5Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 0.2mL of DMF, allowed to dissolve completely, then left open at room temperature for 2 weeks, and then centrifuged (10000 rpm,4 min) to give crystalline form D of the compound of the present application.
2.5 Preparation method of Crystal form E
20.6Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione in solid form prepared in the above preparation example was weighed, added to 10.0mL of ethyl acetate, stirred at room temperature for 1 week, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give crystalline form E of the compound of the present application.
2.6 Preparation method of crystal form F
15.0Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 0.6mL of tetrahydrofuran to completely dissolve it, then 3.0mL of toluene was added to the solution, stirred at room temperature for 1 hour, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give crystalline form F of the compound of the present application.
2.7 Preparation method of Crystal form G
15.0Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 0.8mL of dioxane to completely dissolve it, then 2.4mL of n-heptane was slowly added dropwise to the solution, stirred at room temperature for 1 hour, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give crystalline form G of the compound of the present application.
2.8 Preparation method of crystal form I
19.8Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 3.0mL of acetone, allowed to dissolve completely, and then left open at room temperature for 2 weeks to give crystalline form I of the compound of the present application.
2.9 Preparation method of crystal form J
14.9Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione prepared in the above preparation example in solid form was weighed, added to 0.5mL of butyl formate to completely dissolve it, then 0.5mL of methylene chloride was added to the solution, stirred at room temperature for 1 week, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give crystalline form J of the compound of the present application.
2.10 Preparation method of crystal form K
15.0Mg of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione in solid form prepared in the above preparation example was weighed, added to 1.0mL of methanol, stirred at room temperature for 1 week, and after centrifugation (10000 rpm,4 min), the solid was dried in vacuo at room temperature to give form K of the compound of the present application.
3. (6E) Preparation of crystalline forms of (E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-e-2, 4-dione and fumaric acid
(6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione fumaric acid solid form (15.2 mg) was taken and 1.0mL of acetone was added to prepare a suspension, the suspension was stirred at room temperature for 7 days, the suspension was separated, and the solid was dried in vacuo to give a white solid crystalline form A having an XRPD pattern as shown in FIG. 24.
Biological examples
Cytotoxicity test
1. Cells (i.e., vero cells) were seeded in 96-well plates and incubated in a carbon dioxide incubator at 37 ℃.
2. The compound (i.e., 6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and crystalline form A of fumaric acid) were diluted to different concentrations in culture medium, inoculated into 96-well plates, and 4 wells were repeated for each sample.
3. After 24 hours of treatment of the samples (i.e., solutions of compounds at different concentrations), the cell activity was measured using the CCK8 method, the toxicity of the compounds to the cells was calculated, and the IC 50 value was calculated.
The specific experimental method is as follows:
Vero african green monkey kidney cell CCL-81) was derived from the chinese collection of typical cultures. Culture medium: MEM medium +10% fetal bovine serum.
Crystalline form a of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and fumaric acid was dissolved in 0.1% DMSO and then dissolved in 100 μl MEM medium (containing 10% fetal calf serum) to a final concentration of 10 μΜ,20 μΜ, 50 μΜ, 100 μΜ, 150 μΜ, 300 μΜ, with solvent 0.1% DMSO as a blank control, and MEM medium (containing 10% fetal calf serum) as a negative control.
After digestion of the corresponding host cells, the concentration was adjusted to 5X 10 6/mL, inoculated into 96-well plates at 100. Mu.L/well, and each plate was left with a row of blank wells as a system control and incubated in a carbon dioxide incubator at 37 ℃.
After 24 hours, the plates were removed entirely, medium was removed, and sample and control DMSO were added to the plates separately, 6 wells at each concentration. MEM medium (containing 10% fetal bovine serum) was added to the control wells of the system.
After 48 hours, the activity of the cells was examined using the CCK8 method. The liquid in each well was removed, MEM medium (10% fetal bovine serum) containing 10% CCK8 reagent was added to each well, and after 2 hours of incubation in a 5% carbon dioxide incubator at 37℃the absorbance was measured at 450nm using a microplate reader.
The viability of Vero cells was 89.24% after 48 hours of treatment of cells with the compound at a maximum concentration of 300 μm. Results: for host cell Vero cells, the tested compounds have IC 50 values greater than 300. Mu.M.
Conclusion: the tested compounds are non-cytotoxic to the cells tested (i.e., vero cells) over a relatively wide concentration range, with good safety.
Antiviral experiment
1. Sample preparation
After digestion of the corresponding host cells, the concentration was adjusted to 5X 10 6/mL, inoculated into 12-well plates with 1mL per well. After 24 hours, various concentrations of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and crystalline form A (0.1. Mu.M, 0.5. Mu.M, 0.75. Mu.M, 1. Mu.M, 30. Mu.M) of fumaric acid were mixed with appropriate titres of virus liquid at room temperature and the virus titres used in the experiments are given in Table 1. The medium in the 12-well plate was removed, and the cells were washed with PBS, and PBS was removed, and a mixture of virus and drug was added to the 12-well plate for cell infection. DMSO was used as a blank and serum-free MEM medium was used as a negative control. 2 hours after infection, the solution containing the virus in the well plate was removed and replaced with MEM medium (containing 10% fetal bovine serum) containing crystalline form A of the corresponding concentrations of (6E) -6- [ (6-chloro-2-methyl-2H-indazol-5-yl) imino ] -3- [ (1-methyl-1H-1, 2, 4-triazol-3-yl) methyl ] -1- (2, 4, 5-trifluorobenzyl) -1,3, 5-triazin-E-2, 4-dione and fumaric acid. After more than half of the cells in DMSO-treated wells of the control group in the 12-well plate had cytopathic effect (cytopathic effect, CPE), the supernatant from each well was collected and the supernatant collected was used to infect the corresponding host cells for TCID 50 assay. Three wells per concentration.
2. The titre of the virus was determined using TCID 50 as follows:
Corresponding host cells are inoculated into a 96-well plate according to the amount of 2X 10 4 cells/well, and the titer can be measured after the cell confluency reaches more than 70%. The virus stock was first diluted according to a 10-fold gradient from 10 -1 to 10 -7. After the completion of dilution, the culture broth in the 96-well plate was discarded, and the virus dilutions were added to the 96-well plate, 100. Mu.L of the virus broth was added to each well, 8 wells were repeated for each dilution, and serum-free MEM (minimum essential medium) was added to 8 wells as a negative control, and incubated in an incubator containing 5% carbon dioxide at 37℃for 1 hour. After completion of incubation, the supernatant was discarded, and 100. Mu.L of MEM containing 2% FBS was added to each well, and the mixture was incubated in an incubator at 37℃with 5% CO 2 for a period of time determined depending on the type of virus. The occurrence of cytopathic effect (CPE) in each well was then observed with an inverted microscope and the number of CPE-positive wells per dilution was recorded. Finally, the titer of the virus was calculated according to the Reed-Muench calculation method (Stephan, 1977) and the virus inhibition was calculated according to the following formula.
Inhibition = (1-viral titer in drug-treated group/viral titer in vehicle-treated group) ×100%
The half-maximal effective concentration of the compound against the virus (EC 50) was determined as follows:
EC 50 calculation method: firstly, calculating the Inhibition rate corresponding to each concentration by using EXCEL software, then opening GRAPHPAD PRISM 8.0.0 software, creating a Group chart ①, inputting a medicine concentration value in an X column, inputting the corresponding Inhibition rate in a Group A column, clicking analysis ze ②, clicking Transform concentrations (X), clicking OK, ③ clicking Transform to logarithms, clicking OK, ④ clicking Transform X to perform curve fitting, clicking analysis ze, clicking OK, ⑤ clicking Dose-response-Inhibition, clicking Log (inhibitor) vs. response-Variable slope (four parameters), clicking OK, and viewing the fitted EC 50 value in a non-lin fit column.
Therapeutic Index (TI) =half toxic concentration (IC 50)/half effective concentration (EC 50)
TABLE 1 anti-herpes simplex virus experiments and results thereof
Table 1, below
Sequence number | Viral titer | Infectious virus titer | Infection time | Host cell half CPE |
1 | 3.2×107TCID50/ml | 3.2×106TCID50/ml | 2h | About 4d appear |
2 | 5.0×107TCID50/ml | 1.0×107TCID50/ml | 2h | About 4d appear |
Conclusion:
As can be seen from the above table and FIG. 1, the test compounds have inhibitory effects on both herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).
The titer of the type 1 herpes simplex virus (GDV 011) after being treated by 30 mu M of the test compound is reduced from 10 6.70TCID50/mL to undetectable, and the titer of the type 2 herpes simplex virus (GDV 017) after being treated by 30 mu M of the test compound is reduced from 10 7.73TCID50/mL to 10 1.68TCID50/mL.
The test compound has an EC 50 value of less than 0.1 μm for herpes simplex virus type 1 (GDV 011) and an EC 50 value of less than 0.1 μm for herpes simplex virus type 2 (GDV 017).
The therapeutic index TI of the test compound to the herpes simplex virus is more than 3000.
Conclusion: the tested compounds have an inhibitory effect on the corresponding herpes simplex virus in host cells and have high therapeutic safety.
The foregoing embodiments have been provided for the purpose of illustrating the general principles of the present invention, and are not meant to limit the scope of the invention, but to limit the scope of the invention.
Claims (9)
1. The use of a compound of formula (I), or an isomer, salt, N-oxide, metabolite, solvate, salt of a solvate, crystalline form, prodrug, complex, co-crystal, co-amorphous or isotopic form thereof, in the manufacture of a medicament for the treatment or prophylaxis of a herpes simplex virus infection and associated diseases or conditions in a subject,
Wherein the method comprises the steps of
Each R 1、R2、R3、R4、R5、R6、R7 is independently H or substituted or unsubstituted C 1-C6 alkyl;
X is halogen;
m is 0,1,2 or 3;
n is 0, 1,2, 3,4 or 5;
preferably, the substituents are one or more groups independently selected from C 1-C6 alkyl, C 1-C6 alkoxy, C 1-C6 alkylthio, C 1-C6 alkylamino, halogen, mercapto, hydroxy, nitro, cyano, C 3-C6 cycloalkyl, C 2-C6 heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate;
preferably, each X is the same or different from each other.
2. The use according to claim 1, wherein R 1 and R 2 are each independently unsubstituted C 1-C6 alkyl; and/or, R 3、R4、R5、R6、R7 are each independently H.
3. Use according to claim 1 or2, wherein X is fluorine or chlorine; m is 1 or 2; and/or n is 2,3 or 4.
4. The use according to any one of claims 1-3, wherein when n is 3, X is a2, 3, 4-position substituent, a2, 3, 6-position substituent, a2, 4, 5-position substituent, a2, 5, 6-position substituent, a 3,4, 5-position substituent, a 3,5, 6-position substituent, or a 4,5, 6-position substituent.
5. The use according to any one of claims 1 to 4, wherein the compound of formula (I) is
Or a salt, isomer, N-oxide, metabolite, solvate, salt of a solvate, crystalline form, prodrug, complex, co-crystal, co-amorphous or isotopic form thereof.
6. The use according to claim 5, wherein the compound of formula (I) forms a crystalline form with fumaric acid;
Preferably, the crystalline form is crystalline form a, which uses Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any three selected from 10.94, 19.06, 23.50, 24.66;
Preferably, crystalline form a, which uses Cu-ka radiation, further comprises any one or more of 9.5, 13.81, 18.61, 22.59, 23.8, or further comprises any one or more of 7.81, 10.14, 11.50, 11.93, 12.31, or further comprises any one or more of 14.73, 20.87, 21.49, 21.97, 25.39, characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 °;
More preferably, crystalline form a uses Cu-ka radiation, and the characteristic diffraction peaks of the X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° include any one or more of 10.94, 19.06, 23.50, 24.66, 9.5, 13.81, 18.61, 22.59, 23.8, or further include any one or more of 7.81, 10.14, 11.50, 11.93, 12.31, and/or further include any one or more of 14.73, 20.87, 21.49, 21.97, 25.39;
Most preferably, crystalline form a uses Cu-ka radiation and an X-ray powder diffraction pattern expressed in terms of 2θ values ± 0.2 ° is shown in fig. 24;
And/or the number of the groups of groups,
Preferably, the molar ratio of the compound of formula (I) to fumaric acid in the crystalline form is 1:1.
7. The use according to any one of claims 1-6, wherein the herpes simplex virus comprises herpes simplex virus type 1 and/or herpes simplex virus type 2; preferably, herpes simplex virus type 1 (HSV-1) is herpes simplex virus type 1 GDV011; and/or, herpes simplex virus type 2 (HSV-2) is herpes simplex virus type 2 GDV017.
8. The use according to any one of claims 1-7, wherein the herpes simplex virus infection and its associated diseases or disorders include diseases or disorders caused by herpes simplex virus, such as clinical herpes (primary and recurrent), herpetic eczema (primary) and traumatic herpes (primary or recurrent), gingivitis (primary), vulvovaginitis (primary, recurrent), genital herpes (primary, recurrent), keratoconjunctivitis (primary and recurrent), meningoepithymitis (primary), neonatal herpes simplex virus infection, aseptic meningitis, and/or herpes labialis.
9. The use of any one of claims 1-8, wherein the subject is a human, such as a child, adult, or elderly human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211365282 | 2022-10-21 | ||
CN2022113652826 | 2022-10-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117917240A true CN117917240A (en) | 2024-04-23 |
Family
ID=90730007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311319192.8A Pending CN117917240A (en) | 2022-10-21 | 2023-10-12 | Use of compounds for the treatment of herpes simplex virus infection and related diseases or conditions |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117917240A (en) |
-
2023
- 2023-10-12 CN CN202311319192.8A patent/CN117917240A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10662198B2 (en) | Polymorphic form of compound, preparation method and use thereof | |
EP2961755B1 (en) | Trifluoromethyl-substituted ring-fused pyrimidines and use thereof | |
CN102448952B (en) | Antiviral compounds and uses thereof | |
EP2089380B1 (en) | Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors | |
DE102005019712A1 (en) | Dipyridyl-dihydropyrazolone and its use | |
HRP920759A2 (en) | A process for the production of 3h-pteridinones-4 and medicinal preparations containing them | |
AU2019424375B2 (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof | |
EP0484988A1 (en) | 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives and pharmaceutical composition containing the same | |
CN114591303A (en) | High purity compounds and methods for purifying or preparing compounds | |
JP2022549923A (en) | Crystal forms of N-hetero pentacyclic ring-containing capsid protein assembly inhibitors and uses thereof | |
WO2022031838A1 (en) | Compositions for modulating splicing | |
JPH037257A (en) | Pyridine derivative and psychotropic agent containing the derivative as active ingredient | |
CN117917240A (en) | Use of compounds for the treatment of herpes simplex virus infection and related diseases or conditions | |
CN100415745C (en) | Imidazopyridine-derivatives as inductible NO-synthase inhibitors | |
CN109071515A (en) | Substituted annelated pyrimidines ketone compound | |
CN117917244A (en) | Use of compounds for the treatment of diseases caused by rubella virus | |
JP2010516668A (en) | Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same | |
CN117917243A (en) | Use of compounds for the treatment of varicella zoster virus induced diseases | |
CN117917239A (en) | Use of compounds for the treatment of parainfluenza virus-induced diseases | |
CN117917241A (en) | Use of compounds for the treatment of enterovirus-induced diseases | |
CN117917242A (en) | Use of compounds for the treatment of diseases caused by respiratory syncytial virus | |
CN105130884A (en) | 5-methyl-2(1H)pyridone derivatives, preparation method and applications thereof | |
AU2004308578B2 (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
CN117917238A (en) | Use of compounds for the treatment or prophylaxis of diseases caused by influenza virus | |
TWI830884B (en) | Crystal forms of phosphodiesterase inhibitors, their preparation methods and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |